For Immediate Release:
Dec. 9, 2013

Contact Information:
Tom Manning, Director of Marketing
Telephone: +1.630.256.7527, ext. 103
E-mail: tmanning@slas.org

Edward Kai-Hua Chow, Ph.D., Named JALA Deputy Editor-in-Chief

CHICAGO – The Society for Laboratory Automation and Screening (SLAS) has appointed Edward Kai-Hua Chow, Ph.D., of the University of Singapore, to the position of Deputy Editor-in-Chief for the Journal of Laboratory Automation (JALA).

As JALA Deputy Editor-in-Chief, Dr. Chow will work closely with JALA Editor-in-Chief Dean Ho, Ph.D., of the University of California, Los Angeles, throughout 2014 to transition planning initiatives and management responsibilities. Dr. Ho will end his tenure and Dr. Chow will assume full responsibilities as JALA Editor-in-Chief effective Jan. 1, 2015.

The Editor-in-Chief is the principal architect and arbiter of JALA’s scientific content. The Editor-in-Chief leads the strategic advancement of JALA’s scientific content in line with the SLAS mission and goals; and actively seeks and solicits the best science from the best scientists to be published in JALA.

“We are impressed with Dr. Chow’s energy and vision for JALA,” says SLAS CEO Greg Dummer. “Ed has been an active volunteer leader, serving JALA as an associate editor, guest editor, editorial board member, author and manuscript reviewer. He also has conducted Author Workshops and made scientific presentations at SLAS Annual Conferences. Plus, Ed’s first-hand understanding of scientific communities beyond the U.S., particularly in Asia, directly supports the priorities of the SLAS Strategic Plan.”

Dr. Chow received his Ph.D. in Molecular Biology from the University of California, Los Angeles; and his B.A. in Molecular and Cell Biology-Immunology from the University of California, Berkeley. Dr. Chow worked as a postdoctoral fellow in Nobel Laureate in Medicine J. Michael Bishop’s laboratory at the University of California, San Francisco; and was a co-founder and board member of Biotic Laboratories, Culver City, Calif.

MORE
Since 2012, Dr. Chow has held the position of assistant professor/junior principal investigator with the Cancer Science Institute of Singapore, Department of Pharmacology, Yong Loo Lin School of Medicine, National University of Singapore.

Dr. Chow’s research focuses on Cancer Stem Cells: Markers, Mechanisms and Nanomedicine, including identification of markers for hepatic tumor initiating cells; molecular mechanisms behind how specific oncogenes form these cells; and evaluation of nano-based drug delivery platforms to target cancer stem cells.

For more information about SLAS, including JALA and the recently updated SLAS Strategic Plan, visit www.slas.org. For more information about Edward Kai-Hua Chow, Ph.D., visit his laboratory's website at http://www.csi.nus.edu.sg/wp/the-team/principal-investigators/edward-kai-hua-chow.

**The Society for Laboratory Automation and Screening (SLAS)** is an international community of more than 15,000 individual scientists, engineers, researchers, technologists and others from academic, government and commercial laboratories. The SLAS mission is to be the preeminent global organization providing forums for education and information exchange and to encourage the study of, and improve the practice of laboratory science and technology. For more information, visit www.SLAS.org.

SLAS publishes two internationally recognized, MEDLINE-indexed journals in partnership with SAGE Publications. **The Journal of Laboratory Automation (JALA) and Journal of Biomolecular Screening (JBS)** uniquely serve laboratory science and technology professionals who work primarily in life science R&D. Together, JALA and JBS address the full spectrum of issues that are mission-critical to this important audience, enabling scientific research teams to gain scientific insights, increase productivity, elevate data quality, reduce lab process cycle times and enable experimentation that otherwise would be impossible.

Specifically, JALA explores ways in which scientists adapt advancements in technology for scientific exploration and experimentation. In direct relation to this, JBS reports how scientists use adapted technology to pursue new therapeutics for unmet medical needs, including assay development, identification of chemical probes and target identification and validation in general.

* * * * *